Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.2900
-0.0060-2.03%
Volume:141.68K
Turnover:41.81K
Market Cap:8.75M
PE:-0.10
High:0.3054
Open:0.2965
Low:0.2807
Close:0.2960
Loading ...

Relmada says independent analysis shows depression treatment unlikely to meet main trial goal

Reuters
·
04 Dec 2024

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile

TIPRANKS
·
04 Dec 2024

Relmada Therapeutics Inc: to Continue to Focus on Development of Rel-P11 for Metabolic Disease

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance Ii Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics Inc - to Evaluate Next Steps for Rel-1017 Program

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics Inc - DMC Did Not Identify Any New Safety Concerns in Reliance Ii Study

THOMSON REUTERS
·
04 Dec 2024

Relmada Therapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS
·
04 Dec 2024

BRIEF-Relmada Therapeutics Initiates Phase 1 Dosing With REL-P11 For Metabolic Disease

Reuters
·
14 Nov 2024

Relmada Therapeutics Inc - Phase 2a Proof-of-Concept Study Expected to Begin in H1 2025

THOMSON REUTERS
·
14 Nov 2024

Relmada Therapeutics Initiates Phase 1 Dosing With Rel-P11 for Metabolic Disease

THOMSON REUTERS
·
14 Nov 2024

Relmada Therapeutics Inc reports results for the quarter - Earnings Summary

Reuters
·
09 Nov 2024

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com
·
08 Nov 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire
·
05 Nov 2024

3 US Penny Stocks To Monitor In October 2024

Simply Wall St.
·
23 Oct 2024

Relmada Therapeutics Raised to Buy From Hold by Jefferies

Dow Jones
·
17 Sep 2024

Jefferies Upgrades Relmada Therapeutics to Buy From Hold, Price Target is $13

MT Newswires Live
·
17 Sep 2024